Starling Oncology (STLNW) Retained Earnings (2019 - 2026)

Starling Oncology (STLNW) has reported Retained Earnings for 8 consecutive years, with -$283.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 14.67% year-over-year to -$283.7 million; the trailing twelve-month figure through Jun 2026 stood at -$283.7 million (down 14.67% YoY), and the FY2025 full-year result was -$271.4 million, down 226.0% from the prior year.
• Retained Earnings eased to -$283.7 million in Q2 2026 per STLNW's latest filing, from -$273.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $236.5 million in Q1 2025 and bottomed at -$283.7 million in Q2 2026.
• Historically, Retained Earnings has averaged $69.6 million across 5 years, with a median of $188.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 1058.78% in 2022, then plunged 226.0% in 2025.
• Over 5 years, Retained Earnings stood at $186.2 million in 2022, then advanced by 9.63% to $204.2 million in 2023, then grew by 5.5% to $215.4 million in 2024, then slumped by 226.0% to -$271.4 million in 2025, then dropped by 4.52% to -$283.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$283.7 million, -$273.9 million, and -$271.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.